Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 6, 2009

View Archived Issues

New Aurora B kinase inhibitors reported in recent Boehringer Ingelheim patent

New mGluR1 and mGluR5 receptor ligands discovered at Gedeon Richter

AstraZeneca identifies novel CRTh2 receptor ligands for respiratory disorders

Novel selective AT2 receptor agonists disclosed by Mitsubishi Tanabe

NVP-BEZ-235 a candidate for ovarian cancer treatment

Novel PDF inhibitors prepared and tested at Il-Dong

Novartis presents fourth quarter highlights

Phase II results for temozolomide in non-small cell lung cancer reported

Toxicity seen with everolimus/tacrolimus regimen in stem cell transplant patients

Prolonged dosing of TLR-7 agonist 852A assessed in cancer patients

Transition Therapeutics completes patient enrollment of phase II TT-223 study

Cytopia successfully concludes phase I oral CYT-997 trial

Raptor completes enrollment in phase IIa nonalcoholic steatohepatitis trial

Adventrx completes enrollment in ANX-514 bioequivalence study

BioDelivery Sciences presents initial phase I Bioral amphotericin B results

King offers new dosage strengths of Avinza for chronic pain

Trial aimed at regenerating insulin-producing capacity gets FDA approval

Oncolys initiates French phase Ib clinical study of Festinavir in HIV patients

Favrille changes name to MMR Information Systems

Oncolytics and the CTRC at UTHSCSA enter collaboration for phase II studies of Reolysin

GlaxoSmithKline and Genmab seek E.U. marketing authorization for Arzerra

Dyax expands antibody discovery collaboration with Biogen

Immunomedics' hPAM4 labeled with yttrium-90 receives fast track designation

Partnership aims to develop proof-of-concept vaccine against Chikungunya virus

UCB meets with FDA to define Cimzia regulatory path in rheumatoid arthritis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...